CA2929286A1 - Traitement de troubles du spectre autistique a l'aide de l'acide glycyl-l-2-methylprolyl-l-glutamique - Google Patents
Traitement de troubles du spectre autistique a l'aide de l'acide glycyl-l-2-methylprolyl-l-glutamique Download PDFInfo
- Publication number
- CA2929286A1 CA2929286A1 CA2929286A CA2929286A CA2929286A1 CA 2929286 A1 CA2929286 A1 CA 2929286A1 CA 2929286 A CA2929286 A CA 2929286A CA 2929286 A CA2929286 A CA 2929286A CA 2929286 A1 CA2929286 A1 CA 2929286A1
- Authority
- CA
- Canada
- Prior art keywords
- mepe
- mice
- syndrome
- treated
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730829P | 2012-11-28 | 2012-11-28 | |
| US61/730,829 | 2012-11-28 | ||
| PCT/US2013/072049 WO2014085480A1 (fr) | 2012-11-28 | 2013-11-26 | Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2929286A1 true CA2929286A1 (fr) | 2014-06-05 |
Family
ID=50828422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2929286A Abandoned CA2929286A1 (fr) | 2012-11-28 | 2013-11-26 | Traitement de troubles du spectre autistique a l'aide de l'acide glycyl-l-2-methylprolyl-l-glutamique |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2928300A4 (fr) |
| JP (1) | JP2016506380A (fr) |
| AU (1) | AU2013352294A1 (fr) |
| BR (1) | BR112015012506A2 (fr) |
| CA (1) | CA2929286A1 (fr) |
| WO (1) | WO2014085480A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180184964A1 (en) * | 2014-06-30 | 2018-07-05 | Cerora, Inc. | System and signatures for a multi-modal physiological periodic biomarker assessment |
| PL3833358T3 (pl) * | 2018-08-10 | 2024-03-04 | New York University | Zastosowanie ligandów agonistycznych receptora igf-2 w leczeniu zespołu angelmana i autyzmu |
| MX2021001596A (es) | 2018-08-10 | 2021-06-08 | Univ New York | Uso de manosa-6-fosfato y sus modificaciones para mejorar la memoria y reducir el daño mental. |
| WO2025169163A1 (fr) * | 2024-02-10 | 2025-08-14 | Teadus Pharma Private Limited | Procédé de synthèse de trofinétide et de ses analogues |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006127702A2 (fr) * | 2005-05-23 | 2006-11-30 | Neuren Pharmaceuticals Limited | Analogues de glycyl-prolyl-glutamate |
| ATE435852T1 (de) * | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
| US8637567B2 (en) * | 2001-05-24 | 2014-01-28 | Neuren Pharmaceuticals Ltd. | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid |
| US8461148B2 (en) * | 2004-09-20 | 2013-06-11 | Icahn School Of Medicine At Mount Sinai | Use of memantine (namenda) to treat autism, compulsivity and impulsivity |
| WO2007106555A2 (fr) * | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Préparations orales de glycyl-2-méthylpropyl-glutamate |
| PL2083811T3 (pl) * | 2006-11-22 | 2017-05-31 | Clinical Research Associates, Llc | Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu |
| US7994127B2 (en) * | 2007-06-08 | 2011-08-09 | Massachusetts Institute Of Technology | Treatment of rett syndrome |
| WO2011146109A2 (fr) * | 2010-05-17 | 2011-11-24 | Mount Sinai School Of Medicine | Procédés et tests pour le traitement de sujets présentant une délétion, une mutation ou une expression réduite de shank3 |
| SI2667715T1 (sl) * | 2011-01-27 | 2017-11-30 | Neuren Pharmaceuticals Limited | Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline |
-
2013
- 2013-11-26 EP EP13858943.7A patent/EP2928300A4/fr not_active Withdrawn
- 2013-11-26 WO PCT/US2013/072049 patent/WO2014085480A1/fr not_active Ceased
- 2013-11-26 BR BR112015012506A patent/BR112015012506A2/pt not_active Application Discontinuation
- 2013-11-26 AU AU2013352294A patent/AU2013352294A1/en not_active Abandoned
- 2013-11-26 CA CA2929286A patent/CA2929286A1/fr not_active Abandoned
- 2013-11-26 JP JP2015545191A patent/JP2016506380A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015012506A2 (pt) | 2017-07-11 |
| JP2016506380A (ja) | 2016-03-03 |
| EP2928300A4 (fr) | 2016-07-13 |
| AU2013352294A1 (en) | 2015-07-09 |
| WO2014085480A1 (fr) | 2014-06-05 |
| EP2928300A1 (fr) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2823218C (fr) | Traitement de troubles du spectre autistique en utilisant l'acide glycyl-l-2-methylprolyl-l-glutamique | |
| US11197856B2 (en) | Bicyclic compounds and methods for their use in treating autism | |
| US20150224164A1 (en) | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid | |
| WO2011147889A1 (fr) | Procédés et composition pharmaceutiques pour le traitement d'un trouble de l'alimentation à début précoce chez un patient | |
| EP2928300A1 (fr) | Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique | |
| US20190091284A1 (en) | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation | |
| US20180117113A1 (en) | Amidated Dopamine Neuron Stimulating Peptide Restoration of Mitochondrial Activity | |
| Ismailova et al. | Lipopolysaccharide-induced depressive-like state and neuroinflammatory responses: differential effects on hippocampus and prefrontal cortex in wild-type mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20171128 |